Chronic infection with hepatitis C virus in patients with elevated or persistently normal serum alanine aminotransferase levels: Comparison of hepatic histology and response to interferon therapy

被引:54
作者
Shiffman, ML
Stewart, CA
Hofmann, CM
Contos, MJ
Luketic, VA
Sterling, RK
Sanyal, AJ
机构
[1] Virginia Commonwealth Univ, Med Coll Virginia, Hepatol Sect, Richmond, VA 23298 USA
[2] Virginia Commonwealth Univ, Med Coll Virginia, Div Surg Pathol, Richmond, VA 23298 USA
关键词
D O I
10.1086/317612
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Ninety-five patients with chronic hepatitis C virus (HCV) infection, 35 with persistently normal serum alanine aminotransferase (ALT) levels, were randomized to treatment with daily interferon (IFN) for 3 months, followed by IFN 3 times weekly (TIW) for 12 months (group A) or TIW for 18 months (group B), Patients with elevated versus normal ALT levels had similar demographic and virologic characteristics but significantly (P < .05) more advanced liver histology (bridging fibrosis and cirrhosis, 37.9% vs. 11,4%). After 3 months of treatment, 38.3% of patients in group A were HCV RNA negative versus 18.8% in group B (P < .05). When the IFN dose was reduced from daily to TIW in group A, the percentage of patients who remained HCV RNA negative declined; sustained virologic response was similar in both groups (10.6% vs. 8.3%). Response to treatment was similar in patients with elevated or normal ALT levels, Persons with chronic HCV infection and persistently normal serum ALT levels have milder liver disease than, and respond to IFN therapy similarly to, persons with elevated ALT levels.
引用
收藏
页码:1595 / 1601
页数:7
相关论文
共 37 条
[1]   Hepatitis C in asymptomatic blood donors [J].
Alter, HJ ;
ConryCantilena, C ;
Melpolder, J ;
Tan, D ;
VanRaden, M ;
Herion, D ;
Lau, D ;
Hoofnagle, JH .
HEPATOLOGY, 1997, 26 (03) :S29-S33
[2]   EPIDEMIOLOGY OF HEPATITIS-C IN THE WEST [J].
ALTER, MJ .
SEMINARS IN LIVER DISEASE, 1995, 15 (01) :5-14
[3]  
[Anonymous], 1997, HEPATOLOGY, V26, pS2
[4]   TREATMENT OF CHRONIC HEPATITIS-C WITH RECOMBINANT INTERFERON-ALFA - A MULTICENTER RANDOMIZED, CONTROLLED TRIAL [J].
DAVIS, GL ;
BALART, LA ;
SCHIFF, ER ;
LINDSAY, K ;
BODENHEIMER, HC ;
PERRILLO, RP ;
CAREY, W ;
JACOBSON, IM ;
PAYNE, J ;
DIENSTAG, JL ;
VANTHIEL, DH ;
TAMBURRO, C ;
LEFKOWITCH, J ;
ALBRECHT, J ;
MESCHIEVITZ, C ;
ORTEGO, TJ ;
GIBAS, A .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (22) :1501-1506
[5]  
Ferreira-gonzalez, 1996, Mol Diagn, V1, P109, DOI 10.1016/S1084-8592(96)70026-7
[6]   A multicenter, randomized trial of daily, high dose interferon-alpha 2b for the treatment of chronic hepatitis C: Prospective stratification by viral burden and genotype. [J].
Fried, MW ;
Shiffman, ML ;
Sterling, RK ;
Weinstein, J ;
Crippin, J ;
Garcia, G ;
Wright, TL ;
Conjeevaram, H ;
Reddy, RK ;
Peter, J ;
Cotsonis, G ;
Nolte, FS .
GASTROENTEROLOGY, 1998, 114 (04) :A1242-A1242
[7]  
Gish RG, 1999, SEMIN LIVER DIS, V19, P35
[8]  
HABER MM, 1995, AM J GASTROENTEROL, V90, P1250
[9]  
Heathcote EJ, 1999, HEPATOLOGY, V30, p316A
[10]   A prospective, community-based evaluation of liver enzymes in individuals with hepatitis C after drug use [J].
Inglesby, TV ;
Rai, R ;
Astemborski, J ;
Gruskin, L ;
Nelson, KE ;
Vlahov, D ;
Thomas, DL .
HEPATOLOGY, 1999, 29 (02) :590-596